Targeted pill tested to control Tough-to-Treat lung cancers
NCT ID NCT03066206
Summary
This study tested an oral medication called poziotinib for people with advanced non-small cell lung cancer that had specific mutations in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors by blocking enzymes that help cancer cells grow. The trial involved 93 participants and was terminated before completion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.